Previous 10 | Next 10 |
BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today ann...
Brickell Biotech (BBI) has initiated its first U.S. Phase 3 (Cardigan I) study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (abnormally excessive sweating in underarms).The 350-subject study will evaluate the safety and efficacy...
Primary axillary h yperhidrosis is estimated to affect over 1 0 million p eople in the U.S . Sofpironium bromide is a retrometabolically designed investigational new chemical entity BOULDER, Colo., Oct. 06, 2020 (GLOBE NE...
Brickell Biotech (BBI) +8% in premarket, after its development partner, Kaken Pharmaceutical received approval to sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan, for the treatment of primary axillary hyperhidrosis (abnormally excessive sweating in u...
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year Brickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in Q4 2020 BOULDER, Col...
BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today an...
AnGes entered into a collaboration agreement with Brickell Biotech (NASDAQ: BBI ) +14% PM ; under which the latter has the right to develop and commercialize the former's proprietary investigational adjuvanted plasmid DNA vaccine intended to prevent COVID-19 in the U...
IBARAKI CITY, Osaka and BOULDER, Colo., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AnGes, Inc. (“AnGes”), announced today a collaboration agreement with Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, through which Brickell has...
Claims directed to novel crystalline forms of sofpironium bromide Patent protection in Japan granted through 2040 BOULDER, Colo., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on develop...
Are You Buying Or Investing In Penny Stocks Investing in penny stocks can be a risky game. When you really think about it, why do you invest, to begin with? Building wealth, assets, etc. Call it what you will but at the end of the day it boils down to 1 thing: money. Investing, trading, scal...
News, Short Squeeze, Breakout and More Instantly...
Brickell Biotech Inc. Company Name:
BBI Stock Symbol:
NYSE Market:
New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Compan...
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early precl...
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoi...